Albumedix has entered into a distribution agreement with reagent supplier Fujifilm Wako Pure Chemical Corporation in Japan and China including Hong Kong. The partnership is aimed to strengthen Albumedix’s commitment to advanced therapy and biopharmaceutical developers in the region. Under the terms and conditions of the agreement, Fujifilm will act as a commercialisation partner and distributor of Albumedix´s recombinant human albumin products (Recombumin), including joint marketing efforts in Japan, China and Hong Kong.
Albumedix has a history of servicing biopharmaceutical developers in Japan and China and has previously invested in the region, recently announcing Drug Master File (DMF) submissions to the Japanese Pharmaceuticals and Medical Device Agency and DMF lodged with the Chinese National Medical Products Administration. Fujifilm is established within these markets, developing and producing reagents to address the needs of life science companies. Together, the companies will work to offer consistent human albumin in the region. Albumedix will continue to support its existing client base in the region.
"With this partnership Albumedix gains a valued and experienced partner with an established presence in Japan, China and Hong Kong. Fujifilm Wako is highly experienced in the advanced therapy and biopharmaceutical space, where Albumedix products have proven to be vital enablers. We look forward to a strong collaboration with Fujifilm Wako in order to enable the continued development of transformative therapies in the region," said Gregor Kawaletz, CCO at Albumedix.
"Albumedix´ products are an integral part of the processing and formulation of advanced therapies and biopharmaceuticals such as vaccines, cell and gene therapies. The high quality and purity along with extensive regulatory documentation and expert support will offer a versatile tool for the customers of Fujifilm Wako. Fujifilm Wako will be working through well-established sales channels and mature network of dealers and local representatives, relying on local language and dedicated specialists to broaden the use of Albumedix products and enable the development of therapies and biopharmaceuticals in the respective territories." Says Mr Kuniaki Okamoto, General Manager, Life Science Development Operations.